Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 1;23(8):95.
doi: 10.1007/s11886-021-01524-0.

Current Status of Catheter-based Mitral Valve Replacement

Elias Rawish  1   2 , Tobias Schmidt  1   2 , Ingo Eitel  1   2 , Christian Frerker  3   4
Affiliations
Review

Current Status of Catheter-based Mitral Valve Replacement

Elias Rawish et al. Curr Cardiol Rep. .

Abstract

Purpose of review: Transcatheter mitral valve replacement (TMVR) has been developed to address the need for an alternative therapeutic option to surgery in patients suffering from severe mitral regurgitation who are at high surgical risk. The present review illustrated the state-of-the-art of catheter-based mitral valve replacement evaluating technical characteristics and early clinical experience of different devices to outline prospects and challenges of TMVR.

Recent findings: Several devices are currently under clinical assessment. Early experience has demonstrated high procedural success of TMVR. However, TMVR faces several possible hurdles such as left ventricular outflow tract obstruction (LVOTO) after prosthesis deployment, access site complications, and thrombotic risk requiring anticoagulatory therapy. Future studies should assess long-term prosthesis stability, optimal anticoagulation regime, and occurrence of paravalvular leakage. The development of smaller TMVR prostheses suitable for transseptal implantation could overcome bleeding complications. In perspective, TMVR may emerge to a clinically relevant therapeutic approach for patients with severe MR at high surgical risk.

Keywords: Mitral regurgitation; TMVR; Transcatheter cardiac therapeutics; Transcatheter mitral implantation; Transcatheter mitral intervention; Transcatheter mitral valve replacement.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Intrepid prosthesis (Medtronic Inc.)
Fig. 2
Fig. 2
Highlife prosthesis (Highlife)
Fig. 3
Fig. 3
Tiara prosthesis (Neovasc)
Fig. 4
Fig. 4
Tendyne prosthesis (Abbott Vascular)
Fig. 5
Fig. 5
Evoque prosthesis (Edwards Lifesciences)
Fig. 6
Fig. 6
Cardiovalve prosthesis (Cardiovalve)
See this image and copyright information in PMC

References

    1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–1011. doi: 10.1016/s0140-6736(06)69208-8. - DOI - PubMed
    1. Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Détaint D, Vanoverschelde JL, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358–1365. doi: 10.1093/eurheartj/ehm001. - DOI - PubMed
    1. Goel SS, Bajaj N, Aggarwal B, Gupta S, Poddar KL, Ige M, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185–186. doi: 10.1016/j.jacc.2013.08.723. - DOI - PubMed
    1. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. New Engl J Med. 2018;379:2307–2318. doi: 10.1056/NEJMoa1806640. - DOI - PubMed
    1. Obadia J-F, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. New Engl J Med. 2018;379:2297–2306. doi: 10.1056/NEJMoa1805374. - DOI - PubMed

Publication types